NewEdge Advisors LLC Has $2.09 Million Stock Position in United Therapeutics Corporation $UTHR

NewEdge Advisors LLC lifted its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 78.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,861 shares of the biotechnology company’s stock after buying an additional 1,698 shares during the quarter. NewEdge Advisors LLC’s holdings in United Therapeutics were worth $2,092,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Callan Family Office LLC acquired a new position in United Therapeutics in the 2nd quarter worth $1,217,000. Nicholas Investment Partners LP boosted its position in shares of United Therapeutics by 478.5% during the fourth quarter. Nicholas Investment Partners LP now owns 4,553 shares of the biotechnology company’s stock worth $2,218,000 after buying an additional 3,766 shares during the period. Canada Pension Plan Investment Board acquired a new position in shares of United Therapeutics during the second quarter worth about $3,359,000. Seven Fleet Capital Management LP bought a new position in shares of United Therapeutics during the fourth quarter worth about $633,000. Finally, Havemeyer Place LP bought a new position in shares of United Therapeutics during the fourth quarter worth about $2,189,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Activity

In other United Therapeutics news, CEO Martine A. Rothblatt sold 9,500 shares of the company’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $501.39, for a total value of $4,763,205.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares in the company, valued at approximately $162,672,475.77. This represents a 2.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Nilda Mesa sold 228 shares of the stock in a transaction dated Monday, September 14th. The stock was sold at an average price of $505.87, for a total transaction of $115,338.36. Following the completion of the transaction, the director owned 5,580 shares of the company’s stock, valued at approximately $2,822,754.60. The trade was a 3.93% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 364,303 shares of company stock worth $190,312,234. 8.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Bank of America reduced their price target on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Morgan Stanley set a $515.00 price objective on shares of United Therapeutics in a research report on Thursday, August 6th. JPMorgan Chase & Co. boosted their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Royal Bank Of Canada dropped their target price on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Finally, Weiss Ratings cut United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, August 27th. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $646.00.

United Therapeutics Price Performance

NASDAQ UTHR opened at $494.63 on Friday. The business has a 50 day simple moving average of $515.48 and a 200 day simple moving average of $540.32. United Therapeutics Corporation has a one year low of $408.75 and a one year high of $609.35. The stock has a market capitalization of $21.21 billion, a P/E ratio of 17.70, a P/E/G ratio of 2.49 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The firm had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. During the same period in the previous year, the firm earned $6.41 EPS. The business’s revenue for the quarter was down 1.9% compared to the same quarter last year. Equities analysts expect that United Therapeutics Corporation will post 26.21 earnings per share for the current year.

United Therapeutics Profile

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company’s products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics’ PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.